Clinical Trials

The purpose of this study is to examine for differences in the structural parts of bone that determine strength in individuals diagnosed with different monoclonal gammopathies (related diseases in which patients have an increased risk of fracture).

This study is being done to see if daratumumab is safe and effective in the treatment of proliferative glomerulonephritis with monoclonal immune deposits (PGNMID) and C3 glomerulopathy associated with monoclonal gammopathy (C3GN). This is an inflammatory disease in the kidney due to the production of abnormal proteins. There are no known standard effective treatments for patients with PGNMID and C3GN secondary to monoclonal gammopathy. These diseases are caused by abnormal production of proteins (monoclonals) by abnormal clones. Daratumamb has been shown to be effective in treating patients with multiple myeloma a disease which also caused by over production of monoclonal ...

This study is being done to obtain blood from patients with gammopathies (the presence of abnormal proteins in the blood). The study doctors wish to test this blood to gain more information about the causes of gammopathy.

The purpose of this study is to collect fresh and banked blood , marrow, and buccal cheek samples to advance research in the realm of monoclonal gammopathies and plasma cell disorders.  To collect survey information for future epidemiologic studies.  

Aim 1: To identify the specific cytogenetic subtypes associated with familial predisposition in MGUS.  Aim 2: To identify the proportion of patients with high risk MGUS among patients with familial MGUS

The primary purpose of this study is to evaluate the risk of progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Multiple Myleoma (MM) and other lymphoproliferative disorders (LPDs), in individuals from high-risk families, through serial monitoring of markers of progression (i.e., M-protein, Free light chain).

The utilization of glutamine by the bone marrow plasma cells in MGUS and MM will be compared between each other after infusion of 13-carbon labelled glutamine.

The goal of the present study is to answer the question of whether there are clinically relevant subtypes of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) that are associated with populations at high risk for developing these conditions using an online survey and submission of de-identified medical information.

The purpose of this study is to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.

The characteristics and role of gut microbiome rare plasma cell disorders- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) and amyloid light-chain (AL) amyloidosis, have not been explored; and their pathophysiology is quite elusive. To help understand rare plasma cell disorders and its association with gut microbiome, we will study the stool samples of newly diagnosed POEMS patients and AL amyloidosis and compare it with patients with newly diagnosed monoclonal gammopathy of undetermined significance and multiple myeloma as well as healthy controls. Moreover, gut microbiome in newly diagnosed POEMS patients will be compared to POEMS patients in remission. It is our overall ...

The purpose of this study is to develop a data-driven approach that enables healthcare providers to “prescribe” exercise in the appropriate dose in a manner analogous to prescribing a drug.